Mennaallah Mahmoud, Ko-Han Lin, Rheun-Chuan Lee, Chien-An Liu
{"title":"Assessment of Y-90 Radioembolization Treatment Response for Hepatocellular Carcinoma Cases Using MRI Radiomics.","authors":"Mennaallah Mahmoud, Ko-Han Lin, Rheun-Chuan Lee, Chien-An Liu","doi":"10.4274/mirt.galenos.2024.59365","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.59365","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the ability of radiomics features extracted from magnetic resonance imaging (MRI) images to differentiate between responders and non-responders for hepatocellular carcinoma (HCC) cases who received Y-90 transarterial radioembolization treatment.</p><p><strong>Methods: </strong>Thirty-six cases of HCC who underwent MRI scans after Y-90 radioembolization were included in this study. Tumors were segmented from MRI T2 images, and then 87 radiomic features were extracted through the LIFEx package software. Treatment response was determined 9 months after treatment through the modified response evaluation criteria in solid tumours (mRECIST).</p><p><strong>Results: </strong>According to mRECIST, 28 cases were responders and 8 cases were non-responders. Two radiomics features, \"Grey Level Size Zone Matrix (GLSZM)-Small Zone Emphasis\" and \"GLSZM-Normalized Zone Size Non-Uniformity\", were the radiomics features that could predict treatment response with the area under curve (AUC)= 0.71, sensitivity= 0.93, and specificity= 0.62 for both features. Whereas the other 4 features (kurtosis, intensity histogram root mean square, neighbourhood gray-tone difference matrix strength, and GLSZM normalized grey level non-uniformity) have a relatively lower but acceptable discrimination ability range from AUC= 0.6 to 0.66.</p><p><strong>Conclusion: </strong>MRI radiomics analysis could be used to assess the treatment response for HCC cases treated with Y-90 radioembolization.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cooccurrence of Capsular Liver Lesions Along with Peritoneal Carcinomatosis and Hematogenous Metastases in Ovarian Cancer Patients on Consecutive <sup>18</sup>F-FDG PET/CT Studies.","authors":"Kemal Ünal, Levent Güner, Erkan Vardareli","doi":"10.4274/mirt.galenos.2024.39269","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.39269","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of our study was to evaluate the cooccurrence of capsular liver lesions along with peritoneal carcinomatosis and hematogenous metastases in other regions of the body in ovarian cancer patients on follow-up F-18 fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) studies.</p><p><strong>Methods: </strong>Consecutive <sup>18</sup>F-FDG PET/CT studies of 54 women with ovarian cancer between August 2012 and January 2020 and a total of 192 scans were analysed retrospectively. All patients had at least one hepatic and/or capsular lesion with high <sup>18</sup>F-FDG uptake and at least two PET/CT examinations.</p><p><strong>Results: </strong>According to interpretation, of 54 patients with hepatic or capsular lesions, 44 (81.4%), 5 (9.3%) and 5 (9.3%) of them were concluded as perihepatic implants, hematogenous liver metastases and both, respectively. Accompanying peritoneal carcinomatosis on follow-up PET/CT images was found in 42 (95.4%) and 3 (60%) patients with solely capsular lesions and solely hematogenous liver metastases, respectively. Extrahepatic hematogenous organ metastases on follow-up PET/CT images were seen in 4 (9.0%) and 3 (60%) patients with solely capsular lesions and solely hematogenous liver metastases, respectively. Lungs, bones, spleen and brain were detected metastases sites.</p><p><strong>Conclusion: </strong>Cooccurrence of peritoneal carcinomatosis in other regions of abdomen was found to be higher in comparison to hematogenous organ metastases on consecutive PET/CT studies of ovarian cancer patients with capsular liver lesions. The primary opinion of the nuclear medicine physician is essential along with the other patient data for differential diagnosis and treatment approach in this particular patient group.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impacts of <sup>18</sup>F-FDG PET/CT Parameters on Differential Diagnosis and Outcome of Patients with Primary Invasive Mucinous and Lepidic Predominant Adenocarcinoma of the Lung.","authors":"Ebru Tatcı, Özlem Özmen, Derya Kızılgöz, Funda Demirağ, Seçkin Bilgiç","doi":"10.4274/mirt.galenos.2024.24571","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.24571","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study was to investigate whether <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) parameters have a role in differentiating invasive mucinous lung adenocarcinoma (IMA) from lepidic predominant lung adenocarcinoma (LPA). Additionally, we compared the <sup>18</sup>F-FDG-PET/CT features between survivors and non-survivors.</p><p><strong>Methods: </strong>Tumors were divided into 2 groups according to CT appearance: Group 1: nodular-type tumor; group 2: mass- or pneumonic-type tumor. Unilateral and bilateral multifocal diseases were detected. Clinicopathological characteristics and PET/CT findings were compared between IMAs and LPAs, as well as between survivors and non-survivors.</p><p><strong>Results: </strong>We included 43 patients with IMA and 14 with LPA. Tumor size (p=0.003), incidence of mass/pneumonic type (p=0.011), and bilateral lung involvement (p=0.049) were higher in IMAs than in LPAs. IMAs had more advanced T, M, and Tumor, Node, and Metastasis stages than in LPAs (p=0.048, p=0.049, and p=0.022, respectively). There was no statistically significant difference in maximum standardized uptake value (SUV<sub>max</sub>) between the IMA and LPA (p=0.078). The SUV was significantly lower in the nodular group than in the mass/pneumonic-type group (p=0.0001). A total of 11 patients died, of whom SUV<sub>max</sub> values were significantly higher in these patients (p=0.031). Male gender (p=0.0001), rate of stage III-IV (p=0.0001), T3-T4 (p=0.021), M1 stages (p=0.0001), multifocality (p=0.0001), and bilateral lung involvement (p=0.0001) were higher in non-survivor.</p><p><strong>Conclusions: </strong>Although CT images were useful for the differential diagnosis of LPAs and IMAs, SUV<sub>max</sub> was not helpful for differentiation of these 2 groups. However, both <sup>18</sup>F-FDG uptake and CT findings may play an important role in predicting prognosis in these patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ç. Soydal, M. H. Baltacıoğlu, M. Araz, Burak Demir, E. Dursun, S. Taşkın, N. O. Küçük, F. Ortaç
{"title":"Prognostic Importance of 18F-FDG Positron Emission Tomography in Uterine Cervical Cancer","authors":"Ç. Soydal, M. H. Baltacıoğlu, M. Araz, Burak Demir, E. Dursun, S. Taşkın, N. O. Küçük, F. Ortaç","doi":"10.4274/mirt.galenos.2024.57984","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.57984","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141828285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Melis Oflas, Duygu Has Şimşek, S. Kuyumcu, Murat Yılmaz Kıran, Y. Şanlı
{"title":"The Utility of 18F-FDG PET/CT in Detecting Multiple Metastases in Papillary Renal Cell Carcinoma","authors":"Melis Oflas, Duygu Has Şimşek, S. Kuyumcu, Murat Yılmaz Kıran, Y. Şanlı","doi":"10.4274/mirt.galenos.2024.02259","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.02259","url":null,"abstract":"The diagnostic performance of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) for primary kidney tumors is limited. Nevertheless, 18 F-FDG PET/CT is valuable for staging renal cell carcinoma (RCC) when suspected metastases coexist, as one-third of patients with RCC have distant metastases upon diagnosis. Herein, we present a 53-year-old male patient with extensive 18 F-FDG-avid metastatic lesions and an 18 F-FDG-avid renal mass, which later revealed RCC","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141830422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chaymae Bensaid, Salah Oueriagli Nabih, Kenza Bouzidi, O. Sahel, Y. Benameur, A. Doudouh
{"title":"Diagnosis of Atypical Medullary Metastasis in Melanoma Using 18F-FDG PET/CT","authors":"Chaymae Bensaid, Salah Oueriagli Nabih, Kenza Bouzidi, O. Sahel, Y. Benameur, A. Doudouh","doi":"10.4274/mirt.galenos.2024.26486","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.26486","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141830344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Büşra Özdemir Günay, Burak Günay, N. Can, Funda Üstün
{"title":"A Rare Malignancy; Primary Peritoneal Serous Carcinoma in Men with 18F-FDG PET/CT and Histopathology","authors":"Büşra Özdemir Günay, Burak Günay, N. Can, Funda Üstün","doi":"10.4274/mirt.galenos.2024.74875","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.74875","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141660353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Petya Nikolova, Valeria Hadzhiyska, Yavor Gramatikov, Stefani Veneva, Georgi Gaydarov, Elena Raycheva, M. Ilcheva
{"title":"A Rare Case of Triple Primary Malignant Neoplasms (RCC and Colon Cancer) Detected by 18F-FDG PET/CT","authors":"Petya Nikolova, Valeria Hadzhiyska, Yavor Gramatikov, Stefani Veneva, Georgi Gaydarov, Elena Raycheva, M. Ilcheva","doi":"10.4274/mirt.galenos.2024.61214","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.61214","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141668677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Comprehensive Analysis of Volumetric <sup>68</sup>Ga-PSMA PET/CT Parameters, Clinical and Histopathologic Features: Evaluation of the Predictive Role.","authors":"Gözde Mutevelizade, Yasemin Parlak, Ceren Sezgin Arıkbası, Gül Gümüşer, Elvan Sayit","doi":"10.4274/mirt.galenos.2024.56933","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.56933","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the relationships between volumetric <sup>68</sup>Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) parameters, Gleason score (GS), prostate-specific antigen (PSA) levels, histopathological data, and metastatic status in newly diagnosed prostate cancer (PCa) patients and to assess the predictive factors for progression despite treatment.</p><p><strong>Methods: </strong>A total of 78 newly diagnosed patients with PCa who had <sup>68</sup>Ga-PSMA PET/CT scans were included. Clinical parameters, histopathological data, and metastatic status were documented, and volumetric parameters of primary prostate lesions were measured. All obtained data were compared statistically.</p><p><strong>Results: </strong>Primary prostate tumor maximum standardized uptake value (SUV<sub>max</sub>) and GS were significantly related to serum PSA levels (p<0.05). PSA levels and SUV<sub>max</sub> values were significantly higher in patients with lymph node metastases than in those without. GS was found to be significantly increased in metastatic patients. PSMA-derived tumor volume (PSMA-TV) and total lesion PSMA of the primary lesion had a significant relationship with PSA value, GS, and regional lymph node metastases. Receiver operating characteristic analysis, conducted in patients with metastatic and localized disease, identified the cutoff value for SUV<sub>max</sub> as 10.85. According to the results of the logistic regression analysis, PSMA-TV was found to be a predictive factor for progression despite treatment.</p><p><strong>Conclusion: </strong><sup>68</sup>Ga-PSMA PET/CT remains an invaluable imaging modality that should be considered first in PCa staging because of its superior compatibility with clinical and histopathologic data. The importance of this method goes beyond diagnostic accuracy; it also extends into the predictive domain, where the PSMA-TV value of primary prostate lesions is a potential predictor of treatment efficacy. This information is valuable for personalizing patient treatment, improving prognostic accuracy, and predicting clinical outcomes.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}